On the Record · Precision Biosciences
Precision Biosciences competitors, on the record
The companies Precision Biosciences itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Precision Biosciences names
| Company | Named in |
|---|---|
| Beam Therapeutics, Inc. | 2025 |
| CRISPR Therapeutics, AG | 2025 |
| Editas Medicine, Inc. | 2025 |
| Intellia Therapeutics, Inc. | 2025 |
| Prime Medicine, Inc. | 2025 |
| Tune Therapeutics, Inc. | 2025 |
| Verve Therapeutics, Inc. | 2025 |
In its own words
Beam Therapeutics, Inc., CRISPR Therapeutics, AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Prime Medicine, Inc., Tune Therapeutics, Inc., Verve Therapeutics, Inc.
Word for word“We principally compete with others developing and utilizing genome and epigenomic editing technology in the human health sector, including companies such as Beam Therapeutics, Inc., CRISPR Therapeutics, AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Prime Medicine, Inc., Tune Therapeutics, Inc., and Verve Therapeutics, Inc.” 10-K for 2025
Read from Precision Biosciences’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-03-12. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.